Harmony Biosciences Holdings, Inc. (HRMY) Tops Q1 Earnings and Revenue Estimates

Financial Performance - Harmony Biosciences reported quarterly earnings of $0.78 per share, exceeding the Zacks Consensus Estimate of $0.59 per share, and up from $0.67 per share a year ago, representing an earnings surprise of 32.20% [1] - The company posted revenues of $184.73 million for the quarter ended March 2025, surpassing the Zacks Consensus Estimate by 0.66%, and an increase from $154.62 million year-over-year [2] Market Performance - Harmony Biosciences shares have declined approximately 12.9% since the beginning of the year, compared to a decline of 3.9% for the S&P 500 [3] - The current consensus EPS estimate for the upcoming quarter is $0.80 on revenues of $204.85 million, and for the current fiscal year, it is $2.89 on revenues of $840.82 million [7] Industry Outlook - The Medical - Biomedical and Genetics industry, to which Harmony Biosciences belongs, is currently ranked in the top 31% of over 250 Zacks industries, indicating a favorable outlook [8] - Empirical research suggests a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can impact stock performance [5]